Pendulum Therapeutics, a biotechnology company specializing in microbiome science, announced that it has expanded its clinical research collaboration with Mayo Clinic.

The next phase of the collaboration, which began in 2013, will include new clinical studies led by Mayo Clinic investigators, evaluating microbiome-based approaches to support bone health in patients undergoing treatment for breast cancer, as well as a study on the gut-skin axis and the role of the microbiome in improving skin health during menopause.

The collaboration reflects a shared commitment to advancing rigorous microbiome research, said Colleen Cutcliffe, PhD, co-founder and CEO of Pendulum Therapeutics. “Our collaboration represents an important milestone in the continued advancement of microbiome science. Together, we are committed to conducting rigorous clinical research that deepens our understanding of how the gut microbiome influences systemic health, from metabolic function to skin health and women’s health.”

Pendulum Therapeutics developed Pendulum Glucose Control through prior research collaborations with the Mayo Clinic. The medical probiotic was clinically shown to reduce A1C in people with Type 2 diabetes.